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Abstract
Collectins are carbohydrate binding proteins that are implicated in innate host defense. The lung collectins, surfactant
proteins A and D (SP-A and SP-D), bind a variety of pathogens in vitro and influence phagocytosis by alveolar
macrophages. In this report we show that SP-D binds endotoxin (lipopolysaccharide, LPS) in vivo in a rat model of acute
respiratory distress syndrome (ARDS). Intratracheal aerosolization of LPS in rats resulted in the typical features of human
ARDS. Total amounts of SP-D, as well as the carbohydrate binding properties of SP-D were measured in lung lavage as a
function of time. The amount of SP-D did not change during 24 h. Interestingly, SP-D in lung lavage isolated from rats
during the first 2 h after LPS treatment, was not able to bind to carbohydrate. Further analysis revealed that the
carbohydrate binding sites of SP-D were occupied by LPS, suggesting that SP-D is an LPS scavenging molecule in vivo.
Electron microscopic analysis indicated that, 1 h after LPS aerosolization, aggregates of SP-D with LPS were found in
lysosomal structures in alveolar macrophages. We conclude that the lung collectin SP-D binds inhaled endotoxin in vivo,
which may help to protect the lung from endotoxin-induced disease. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lipopolysaccharide (LPS) is an important media-
tor of septic shock and acute respiratory distress
syndrome (ARDS) in the setting of sepsis, a life-
threatening in£ammatory lung condition with mor-
tality rates that are still unacceptably high at 50% [1].
LPS is a component of the outer membrane of
Gram-negative bacteria and a powerful pro-in£am-
matory agent. LPS activates leukocytes to release a
wide variety of in£ammatory mediators, which con-
tribute to the pathogenesis of sepsis and ARDS [2].
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The respiratory tract is continuously exposed to
LPS from the cell wall of inhaled Gram-negative
bacteria [3]. For this reason the epithelial surface of
the lung must have an e⁄cient defence system to
protect the gas-exchange function of the alveoli, es-
sential for breathing. The alveolar surface of the lung
is lined with pulmonary surfactant, a mixture of lip-
ids and proteins, which is thought to play a role in
the ¢rst line defence against invading bacteria and
other pathogens [4^6]. One of the known surfactant
proteins, surfactant protein D (SP-D), is thought to
be a molecule of an innate immune system to protect
the lung [7^10].
Firstly, SP-D is a so-called collectin, a protein
which consists of a collagen-like domain and a lectin
domain that binds carbohydrates in a Ca2-depend-
ent manner [7]. This structure allows SP-D to inter-
act with bacteria as well as with phagocytic cells. SP-
D selectively recognizes carbohydrates on the cell
wall of bacterial pathogens with its carbohydrate
binding site and might thus contribute to the lungs’
defence against these pathogens. Furthermore, sev-
eral in vitro studies suggest a role in innate defence
for SP-D. It is known, for example, that SP-D is able
to bind and agglutinate bacteria and viruses [11,12].
It is also known that SP-D can activate neutrophils,
monocytes and alveolar macrophages [6] and that
SP-D is able to bind LPS with its carbohydrate bind-
ing site in vitro [13].
Recently, it was reported that, in rats, SP-D levels
are increased in lung lavage 72 h after intratracheal
LPS instillation in vivo [14]. However, it is not
known whether SP-D is involved in the acute re-
sponse to LPS in LPS-induced disease in vivo, and
whether SP-D is able to bind LPS in the lung, in
vivo. In this study, we used an established model
of ARDS [15], in which LPS is aerosolized intratra-
cheally in rats, to investigate whether the lung col-
lectin SP-D is able to bind LPS in an acute phase
reaction to intratracheally aerosolized LPS.
2. Materials and methods
2.1. Rat model for human ARDS
Forty-¢ve male albino Wistar rats (180^200 g),
obtained from Charles River (Germany) were used
in this study. The animals were kept at a regular 12 h
light/dark cycle, with a temperature of 22 þ 2‡C.
Food and water were given ad libitum.
We used the animal model as described by Van
Helden et al. [15]. Brie£y, the rats were intubated
with an aerosolizer under brief halothane (Albic
BV, Maassluis, The Netherlands) anaesthesia. Endo-
toxin-free Dulbecco’s PBS at pH 7.4 was used to
dissolve LPS (rough LPS from Salmonella Enteritidis,
Sigma, St. Louis, MO, USA) for intratracheal aero-
solization. PBS (0.5 ml; control) or LPS (0.5 ml; 16
mg/kg) dissolved in PBS, was instilled with a mini-
ature nebulizer. The solution was dispersed in the
trachea, just above the bifurcation. This relatively
high dose of LPS was needed to obtain a manifest
clinical picture of ARDS within 24 h. ARDS was
diagnosed in this model 24 h after LPS was aerosol-
ized according to the lung injury score for patients,
which includes the extent of the in£ammatory density
on chest X-rays, the severity of hypoxemia, the de-
cline in lung compliance and changes in respiratory
frequency [16].
At time points 0, 1, 2, 3, 5, 10, 16 and 24 h after
aerosolization 3^5 rats of the PBS-treated group and
the LPS-treated group were killed and broncho-al-
veolar lavage (BAL) was performed with 5 sub-
sequent vol of 8 ml PBS. These vols were pooled
and cells were pelleted by centrifugation (10 min,
150Ug). The supernatant (40 ml, stored at 320‡C)
was used to determine the total amounts of SP-D
and the carbohydrate binding properties of SP-D.
2.2. Rat SP-D ELISA
Total amounts of SP-D in cell-free BAL were
measured by enzyme-linked immunosorbent assay.
The polyclonal anti-rat SP-D antibodies used in
this ELISA were raised in rabbits and do not
cross-react with rat SP-A. Also, the antibodies react
equally well with SP-D in the presence of LPS as in
the absence of LPS. The assay is linear in the range
of 3^100 ng rat SP-D/ml. Rabbit anti-rat SP-D poly-
clonal antibodies were diluted in 0.1 M NaHCO3
bu¡er (pH 9.6) and coated on a polystyrene 96-well
microtiter plate (maxisorb, NUNC, Roskilde, Den-
mark; 50 Wl/well, 16 h, 4‡C). After coating, the mi-
crotiter plate was blocked with 3% non-fat dried milk
(Protifar, Nutricia, Zoetermeer, The Netherlands) in
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washing solution (50 mM Tris-HCl, 150 mM NaCl,
0.05% Tween-20, pH 7.4, 200 Wl/well) for 60 min at
22‡C. Then the plate was washed six times in wash-
ing solution. Cell-free BAL samples were diluted in
washing solution containing 0.1% BSA and 50 Wl of
the samples was applied to each well of the microtiter
plate. After 1 h of incubation at 22‡C, the plate was
washed six times in washing solution and a biotin-
conjugated rabbit anti-rat SP-D polyclonal antibody,
diluted in washing solution containing 0.1% BSA,
was applied to the plate (50 Wl/well, 22‡C, 1 h). After
washing the plate six times in washing solution,
the bound biotin-conjugated antibodies were de-
tected with horseradish peroxidase-conjugated strep-
tavidin (0.1 Wg/ml, Sigma, St. Louis, MO, USA),
diluted in washing solution containing 0.1% BSA
(50 Wl/well). After 1 h incubation at 22‡C the plate
was stained with 150 Wl/well tetramethylbenzidine re-
agent (100 Wg tetramethylbenzidine (Merck, Darm-
stadt, Germany)/ml, 1 mM H2O2 in 0.1 M citric
acid bu¡er, pH 4.0). The reaction was stopped by
adding 50 Wl 2 M H2SO4 and absorption was meas-
ured at 450 nm.
2.3. Enzyme-linked mannan binding assay
Carbohydrate binding properties of SP-D in cell-
free BAL were measured by an enzyme-linked man-
nan binding assay. Mannan (from Saccharomyces
cerevisiae, Sigma, St. Louis, MO, USA) was acti-
vated by partial periodate oxidation, using condi-
tions that result in oxidation of about 1 out of 10
mannan saccharide subunits. Brie£y, 100 mg mannan
was dissolved in 1.5 ml 40 mM NaIO4 (pH 7.0).
After incubation (1 h, 22‡C), the partially oxidized
mannan was dialyzed against demineralized water.
The aldehyde groups of the activated mannan were
coupled to primary amino groups of BSA as follows.
One ml of activated mannan solution (10 mg/ml in
0.2 M H3BO3, 100 mM NaCNBH3, pH 9.0) was
mixed with 1 ml BSA solution (10 mg/ml in demin-
eralized water). After coupling (16 h, 4‡C) the non-
reacted aldehyde groups were blocked by addition of
0.1 ml ethanolamine (1 M, pH 9.0) and incubated for
1 h at 22‡C. The BSA-conjugated mannan was dia-
lyzed against 50 mM Tris-HCl, 5 mM CaCl2 (pH
7.5).
For the enzyme-linked mannan binding assay, the
BSA-conjugated mannan was dissolved in 0.1 M
NaHCO3 bu¡er (pH 9.6) at a concentration of 20
Wg/ml, and coated on a polystyrene 96-well microtiter
plate for 16 h at 4‡C. After coating the BSA-conju-
gated mannan to the plate, the procedure is the same
as for the rat SP-D ELISA, except that all bu¡ers
used in this assay have a ¢nal concentration of 5 mM
CaCl2. To study whether the carbohydrate binding
sites of SP-D were occupied by LPS after LPS aero-
solization, cell-free lavage samples were pretreated
with TBS-EDTA (10 mM Tris-HCl, 150 mM NaCl,
0.1% BSA, 0.05% Tween-20 and 2.5 mM EDTA) for
1 h at 37‡C, prior to applying these samples to the
blocked mannan-BSA coated plates in the presence
of calcium ions.
2.4. Puri¢cation of rat SP-D
Rats were treated with silica to induce lipoprotein-
osis [17]. Lungs of these rats were washed four
times with 8 ml TBS (5 mM Tris-HCl, 150 mM
NaCl, pH 7.4). Cells were removed by centrifugation
(150Ug, 10 min, 4‡C), and the cell-free lavage was
centrifuged for 2 h at 28 000Ug at 4‡C and the sur-
factant fraction was removed. The high speed super-
natant was concentrated with an Amicon YM 30
membrane (Millipore, Etten-Leur, The Netherlands).
Solid ammonium sulfate was added to the concen-
trated supernatant to a ¢nal concentration of 5%
saturation and centrifuged (20 min, 10 000Ug,
4‡C). The pellet was discarded and the remaining
proteins of the supernatant were concentrated by
addition of solid ammonium sulfate to a ¢nal con-
centration of 60% saturation, and precipitated by
centrifugation (20 min, 10 000Ug, 4‡C). The precipi-
tated proteins were dissolved in TBS and extensively
dialyzed against TBS (50 mM Tris-HCl, 150 mM
NaCl, pH 7.4). Before the protein sample was ap-
plied to a maltosyl-agarose column (Sigma) 1 M
CaCl2 was added to a ¢nal concentration of 5 mM.
After application of the sample to the column, the
column was washed extensively with TBS-Ca (50
mM Tris-HCl, 500 mM NaCl (high salt), 5 mM
CaCl2, pH 7.4) and SP-D was eluted from the col-
umn with TBS-EDTA (50 mM Tris-HCl, 150 mM
NaCl, 5 mM EDTA, pH 7.4). SP-D appeared as a
single 43 kDa band on SDS-PAGE under reducing
conditions.
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2.5. Mannan binding of SP-D after incubation of
SP-D with LPS in vitro
We investigated whether in vitro incubation of SP-
D with LPS resulted in decreased binding to carbo-
hydrate. 50 Wl of puri¢ed rat SP-D (0^10 ng/well)
was incubated with 50 Wl LPS (0^5 Wg/well), both
diluted in TBS-Ca (50 mM Tris-HCl, 150 mM
NaCl, 5 mM CaCl2, pH 7.4) containing 0.05%
Tween-20, in a 96-well microtiter plate. After incu-
bation for 1 h at 37‡C, the SP-D-LPS solutions were
transferred to a blocked mannan-BSA coated micro-
titer plate in the presence of calcium ions and the
procedure for the enzyme-linked mannan binding as-
say was followed as described above.
2.6. FITC-labeled LPS aerosolization
Six rats were used in this experiment. We used the
rat model for ARDS as described above, but in this
study FITC-labeled LPS (from S. Enteritidis, Sigma)
was intratracheally aerosolized. The FITC-labeled
LPS was mixed with unlabeled LPS in a 1:3 ratio.
At 1, 10 and 24 h after aerosolization rats were
killed, BAL was performed, cells were pelleted and
total amounts of SP-D as well as the carbohydrate
binding ability of SP-D in the cell-free BAL were
measured.
2.7. Electron microscopy
Cell pellets were ¢xed (2% (w/v) paraformaldehyde
and 0.5% glutaraldehyde in PBS) overnight at 4‡C.
Subsequently the samples were centrifuged (6000Ug,
10 min) and the pellet was resuspended in PBS con-
taining 50 mM glycine (pH 7.4) to block free alde-
hyde groups. After 10 min the procedure was re-
peated and the resuspended samples were left for 1
h in the PBS/glycine. Samples were centrifuged for 10
min (6000Ug) and the pellet was resuspended in 10%
(w/v) gelatine in 0.1 M sodium phosphate bu¡er (pH
7.4) at 37‡C. Subsequently, the samples were centri-
fuged for 2 min at 9500Ug. Samples were cut out the
tube and placed in ¢xative (2% (w/v) paraformalde-
hyde and 0.5% glutaraldehyde in PBS). Ultrathin
cryosections were cut at 3120‡C on a Reichert Ul-
tracutS/FCS (Leika Aktiengesellschaft, Vienna, Aus-
tria) using a cryo diamond knife (Drukker, Cuyk,
The Netherlands) and were transferred to formvar
carbon coated nickel grids. Thawed ultrathin cryo-
sections were incubated in the following solutions:
PBS/glycine (15 min), block bu¡er (5% BSA, 0.1%
cold water ¢sh skin gelatin (Aurion, Wageningen,
The Netherlands) in PBS, pH 7.4, 30 min), incuba-
tion bu¡er (0.1% BSA-C (Aurion, Wageningen, The
Netherlands) in PBS, pH 7.4, 5 min), rabbit anti-rat
SP-D in incubation bu¡er (1 h), incubation bu¡er
(3U10 min), protein A-gold particles (10 or 15 nm,
1 h), incubation bu¡er (3U10 min), rabbit anti-FITC
(Molecular Probes, Eugene, OR, USA) in incubation
bu¡er (1 h), incubation bu¡er (3U10 min), protein
A-gold particles (10 or 15 nm, 1 h), incubation
bu¡er (3U10 min), PBS (2U5 min), 2% glutaral-
dehyde in PBS (2 min), PBS (2U5 min), distilled
water (4U5 min), 2% uranyl acetate-oxalate (pH
7.4, 10 min). Stained cryosections were embedded
in 1.8% methylcellulose containing 0.3% uranyl ace-
tate. Immunogold-labeled cryosections were ob-
served and photographed in a Philips CM10 electron
microscope (Philips, Eindhoven, The Netherlands) at
80 kV.
3. Results
3.1. Rat model for human ARDS
Within 24 h LPS-treated rats showed typical signs
of human ARDS, according to the lung injury score
for patients [16]. Furthermore, the amount of protein
in the cell-free BAL increased severely in the LPS-
treated rats [15]. Ten h after LPS was aerosolized the
amount of protein reached a plateau at which the
amount of protein was 16-fold higher than before
LPS aerosolization. Also, the number of neutrophils
in the total lavage increased gradually in time and
was signi¢cantly increased after 5 h [15]. Further-
more, TNF-K levels in the cell-free BAL increased
severely in the ¢rst h after LPS was aerosolized
and peaked at 5 h after treatment [15].
3.2. Total amounts of SP-D
When total amounts of SP-D were measured in
cell-free BAL, no signi¢cant di¡erences were ob-
served between the LPS-treated group and the con-
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trol group (Fig. 1). The amount of SP-D did not
change over time (Fig. 1).
3.3. Carbohydrate binding properties of SP-D
Intratracheally aerosolized LPS decreased the abil-
ity of SP-D to bind to mannan (Fig. 2). During the
¢rst 2 h after LPS aerosolization, the percentage of
SP-D bound to mannan decreased to less than 10%
compared to the initial percentage of binding. At
later time points, 10, 16 and 24 h after aerosoliza-
tion, the percentage of SP-D bound to mannan-BSA
was still signi¢cantly decreased by 30^40% in the
LPS-treated rats, compared with the control group.
To study whether the decreased percentage of SP-
D bound to mannan after LPS aerosolization was
caused by LPS occupying the Ca2-dependent carbo-
hydrate binding sites of SP-D, the lung lavage sam-
ples were pretreated with EDTA, prior to application
to a blocked mannan-BSA coated plate in the pres-
ence of calcium ions. We found that EDTA pretreat-
ment of the cell-free BAL samples from LPS-treated
rats increased the amount of SP-D bound to mannan
(Fig. 3). During the ¢rst h after LPS aerosolization,
the percentage of SP-D bound to mannan was in-
creased by 234%. This supports the previous ¢nding
that the ability of SP-D to bind mannan was espe-
cially decreased during the ¢rst h after LPS-aerosol-
ization. At 16 and 24 h after aerosolization, EDTA
pretreatment of lung lavage samples from LPS-
treated rats did not increase the percentage SP-D
bound to mannan. EDTA pretreatment of the lung
lavage samples from the control rats did not have
any e¡ect on the percentage of SP-D bound to man-
nan (Fig. 3).
3.4. Mannan binding of SP-D after incubation of
SP-D with LPS in vitro
Preincubation of puri¢ed rat SP-D with LPS in
vitro also decreased the ability of SP-D to bind to
mannan (Fig. 4). When puri¢ed rat SP-D was incu-
bated with 5 Wg LPS, prior to application to a man-
nan-BSA coated plate, the percentage of SP-D
bound to mannan decreased to less than 5% com-
Fig. 1. Total amounts of SP-D in broncho-alveolar lavage, de-
termined by sandwich ELISA. No di¡erence was observed be-
tween the LPS-treated group (b) and the control group (a)
(n = 3). Data are represented as mean þ S.E.M. of triplicate de-
terminations. The data are representatives of one of two inde-
pendent experiments.
Fig. 2. Carbohydrate binding properties of SP-D in broncho-al-
veolar lavage, determined by the enzyme-linked mannan bind-
ing assay. SP-D from the LPS-treated rats (b) is not able to
bind to mannan immediately after aerosolization compared to
SP-D from control rats (a) (n = 3). Data are represented as
mean þ S.E.M. of triplicate determinations. The data are repre-
sentatives of one of two independent experiments.
Fig. 3. E¡ect of EDTA pretreatment on carbohydrate binding
properties of SP-D in the LPS-treated group (b) and the con-
trol group (a) (n = 3). Results are expressed as the % increase
in carbohydrate binding compared to the carbohydrate binding
before EDTA pretreatment. Data are represented as mean of
triplicate determinations. The data are representatives of one of
two independent experiments.
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pared to the binding of SP-D to mannan in the ab-
sence of LPS (Fig. 4).
3.5. FITC-labeled LPS aerosolization
Rats were treated with FITC-labeled LPS to de-
termine the fate of LPS in the lung after aerosoliza-
tion. The observed e¡ects of FITC-labeled LPS aero-
solization on the lungs were similar to those observed
after aerosolization with unlabeled LPS. Further-
more, the amount of SP-D in the cell-free BAL of
the FITC-LPS-treated rats did not change over time,
and SP-D of the FITC-LPS-treated rats was not able
to bind to mannan immediately after FITC-LPS was
aerosolized.
Electron microscopic analysis showed that, imme-
diately after aerosolization of FITC-labeled LPS, SP-
D colocalizes with LPS in lysosomal structures in
alveolar macrophages (Fig. 5a). In contrast, 24 h
after aerosolization of FITC-labeled LPS, hardly
any SP-D could be observed in the alveolar macro-
phages, while FITC-label was still present in the
macrophages (Fig. 5b). Furthermore, hardly any
SP-D could be detected in the alveolar macrophages
of control rats (Fig. 5c).
4. Discussion
In this study we show that SP-D is involved in the
acute phase reaction to intratracheally aerosolized
endotoxin in a rat model for ARDS. Evidence is
provided that SP-D binds free LPS in the lung im-
mediately after LPS was aerosolized. During the ¢rst
2 h after LPS aerosolization, 92% of the SP-D from
the LPS-treated rats was not able to bind to carbo-
hydrate, in comparison to SP-D from the control
rats. Although we were not able to design a good
method to show directly that LPS is bound to SP-
D in vivo, the results suggest that the carbohydrate
Fig. 4. Carbohydrate binding properties of rat SP-D after in vi-
tro preincubation with LPS. Incubation of SP-D with LPS de-
creased the ability of SP-D to bind to mannan considerably.
Data are expressed as % of binding relative to binding of 10 ng
SP-D to mannan in the absence of LPS. a: 10 ng SP-D; b: 5 ng
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binding sites of the SP-D molecules in LPS-treated
rats are occupied by LPS.
Furthermore, it was shown that EDTA pretreat-
ment of lung lavage samples of LPS-treated rats in-
creases the percentage of SP-D bound to mannan,
with a maximum increase of 234%, in the ¢rst h after
aerosolization. Because the binding of SP-D to car-
bohydrates is calcium ion dependent, EDTA pre-
treatment of the lung lavage samples may release
the LPS from the carbohydrate binding sites of SP-
D, thus enabling SP-D to bind to mannan again in
the presence of calcium ions. This notion is sup-
ported by results from in vitro studies: preincubation
of puri¢ed rat SP-D with LPS decreased the ability
of SP-D to bind to mannan-BSA coated plates. The
decreased binding of SP-D to mannan as a result of
intratracheally aerosolized LPS cannot be explained
by a lower amount of SP-D present in cell-free BAL
Fig. 5. Ultrathin cryosections of alveolar macrophages double labeled for SP-D and FITC. a: SP-D 15 nm gold, FITC 10 nm gold,
magni¢cation: 42 000U. One h after FITC-LPS was aerosolized, aggregates of SP-D with FITC-LPS are found in lysosomal structures
in the macrophages. b: SP-D 10 nm gold, FITC 15 nm gold, magni¢cation: 38 000U. 24 h after FITC-LPS was aerosolized, FITC-la-
bel was still present in the alveolar macrophages. In contrast, hardly any SP-D (arrow) could be detected in the alveolar macrophages.
c: SP-D 10 nm gold, FITC 15 nm gold, magni¢cation: 45 000U. In control rats hardly any SP-D was observed in the alveolar macro-
phages. Bars are 0.5 Wm.
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of LPS-treated rats, because the total amount of SP-
D did not di¡er between the LPS-treated rats and the
control rats during the course of the experiment. In-
tratracheal aerosolization of rats with FITC-labeled
LPS supports the previous ¢ndings. Electron micro-
scopic analysis of alveolar macrophages in the BAL
showed that immediately after FITC-labeled LPS
aerosolization SP-D colocalized with LPS in lysoso-
mal structures in the alveolar macrophages. Based on
the other experiments in this study, that show bind-
ing of LPS to SP-D immediately after LPS aerosoli-
zation, we conclude that the alveolar macrophages
have phagocytosed SP-D-LPS aggregates. Although
no di¡erences in total SP-D in cell-free BAL could be
detected between the groups, in preliminary experi-
ments, we observed more SP-D in the cell fraction
(mainly macrophages) of the BAL from LPS-treated
rats than in the cell fraction of the BAL of control
rats. This suggests that immediately after LPS aero-
solization, SP-D present in the epithelial lining £uid
binds the inhaled LPS, and is rapidly phagocytosed
by the alveolar macrophages.
The fact that SP-D binds LPS in vivo, in an im-
mediate reaction to intratracheally aerosolized LPS,
extends previous in vitro studies [13]. The results
from the present study support the growing belief
that the lung collectin SP-D is a molecule of an in-
nate immune system. E¡ective immunity depends on
speci¢c as well as innate immunity. The importance
of speci¢c, T-cell mediated and antibody response as
defence against infection is well known. However,
the innate defence mechanisms are very important
to protect the lung against all kinds of potentially
harmful pathogens, when the speci¢c immune re-
sponse has not yet developed. Components of innate
immunity include macrophages, neutrophils, natural
killer cells, cytokines and collectins [18]. In addition
to the lung-speci¢c collectins, SP-D and SP-A, serum
collectins have been described: mannose binding lec-
tin (MBL), CL-43 [19] and conglutinin (in ruminants
[20]). Especially MBL is known to be an acute phase
protein, important in innate immunity [21]. Because
of the structural similarity between the serum and the
lung collectins, the lung collectins might have a sim-
ilar function in the immediate, innate defence of the
lung. The results of this study show that SP-D is
indeed involved in this acute phase reaction, by bind-
ing LPS immediately after aerosolization.
The biological signi¢cance of SP-D binding to free
LPS remains to be established. Several possibilities
should be considered. First of all, by binding free
LPS, SP-D can contribute to the clearance and sub-
sequent inactivation of free LPS that is released at
sites of colonization or infection by Gram-negative
bacteria. Secondly, because SP-D is able to bind LPS
on the cell wall of inhaled Gram-negative bacteria
and is able to a¡ect the phagocytic functions of al-
veolar macrophages, either via the collectin (C1q)
receptor [22] or via a speci¢c SP-D receptor [23,24],
it is possible that SP-D functions as a bridge between
the Gram-negative bacteria and phagocytic cells and
in this way enhances clearance and uptake of the
bacteria by these cells. A third possibility is that
SP-D facilitates mucociliary clearance of LPS or
Gram-negative bacteria by forming complexes [13].
It was reported that SP-D can induce large aggre-
gates of bacteria, which in some cases equalled the
size of alveolar macrophages [11]. These large aggre-
gates can easily be removed from the respiratory
tract. The formation of aggregates is consistent
with the structure of the SP-D molecule, which con-
sists of several carbohydrate binding sites per SP-D
molecule, separated by long collagen arms.
In the rat model for ARDS, we observed an in-
crease of TNF-K in the LPS-treated rats that peaked
5 h after LPS was aerosolized [15]. An important
e¡ect of LPS is the induction of cytokines, like
TNF-K, by macrophages. It would be interesting to
study whether SP-D alone or SP-D/LPS complexes
have an e¡ect on cytokine induction. It is known, for
example, that LPS binding protein (LBP) binds LPS
in the blood and in this way facilitates the transfer of
LPS to the CD14 receptor on monocytes and macro-
phages. LPS, bound to LBP is far more potent in
inducing cytokine production than LPS alone [25].
In contrast, Bactericidal/permeability increasing pro-
tein (BPI) competes with LBP for LPS in the blood-
stream. LPS, bound to BPI, is less potent in inducing
an in£ammatory response than LPS alone [26]. Cur-
rent investigations in our laboratory are aimed to
compare the physiological activities of SP-D with
those of LBP and BPI.
We conclude that the collectin SP-D is a molecule
of innate immunity in the lung. The fact that there is
still no speci¢c designated role for SP-D in the main
function of pulmonary surfactant, which is lowering
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the surface tension of the alveoli to prevent alveolar
collapse at end-expiration, favors a role for SP-D as
a molecule of an innate immune system in the lung.
This innate immune system might be a very fast and
important ¢rst reaction to Gram-negative bacteria
and may help to protect the lung from LPS-induced
disease.
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